Only two new antibiotics are in Phase III trials for gonorrhea: Entasis’ zoliflodacin, in collaboration with the Global Antibiotic R&D Partnership, and GlaxoSmithKline’s gepotidacin in partnership with the US Biomedical Advanced R&D Authority.

Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.

Transparency is the order of the day as Médecins Sans Frontières calls for more disclosure on vaccine deals signed by Sanofi/GSK and other companies. 

Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.